Skip to main content

Table 3 Characteristics of patients receiving different drug regimens in the continuation phase

From: Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure

 

INH + Rifampicin

INH + Rifampicin + ethambutol

Age in years, median, (range)

25 (16–75)

25 (16–76)

Sex, n/N (%)

 Male

46/103 (44.6)

48/101 (47.5)

 Female

57/103 (55.3)

53/101 (52.4)

History of contact with TB, n/N (%)

 a Recent

21/103 (20.3)

20/101 (19.8)

 b Previous

17/103 (16.5)

22/101 (21.7)

 No history of contact

65/103 (63.1)

59/101 (58.4)

Prevalence of HIV

0/103

0/103

Smoker n/N (%)

4/103 (3.8)

10/101 (9.9)

Prevalence of diabetes n/N (%)

8/103 (7.7)

3/101 (2.9)

cBacillary load before treatment n/N (%)

 scanty

10/103 (9.7)

10/101 (9.9)

  + 1

57/103 (55.4)

60/101 (59.4)

  + 2

25/103 (24.2)

12/101 (11.9)

  + 3

11/103 (10.7)

19/101 (18.8)

Chest X-ray n/N (%)

 Cavitary lesions

3/7 (42.9)

4/7 (57.1)

 Non-cavitary infiltrates

49/95 (51.6)

46/95 (48.4)

 Not available

50/102 (49.1)

52/102 (50.9)

  1. n number, N Total number, % percentage
  2. aHistory of contact with active TB case during the course of diagnosis and treatment
  3. bHistory of contact with active TB case before diagnosis and treatment
  4. cGraded as per guidelines of the International Union Against Tuberculosis and Lung Disease